Structure Therapeutics Inc. Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Published: 2026-04-14 17:21:56 ET GPCR

Published on 04/14/2026 at 05:21 pm EDT

Structure Therapeutics Inc. announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development. Mr. Lang most recently served as Chief Legal Officer and Secretary at Metsera Inc., helping to guide the company through its up to $10 billion acquisition by Pfizer.

Prior to Metsera, Mr. Lang served as Chief Business and Legal Officer at Lyell Immunopharma Inc., and held several executive officer positions at Myovant Sciences, where he helped lead the company through Phase 3 clinical development, global approval and commercialization of Myfembree® and Orgovyx®. Mr. Lang also served as the Managing Director and General Manager of Myovant?s European operations in Basel Switzerland where he was responsible for all aspects of Myovant?s ex-US business operations. Earlier in his career Mr. Lang held roles of increasing seniority at Gilead Sciences Inc., and was an attorney at Dechert, LLP.

He received his B.A. in Classical Studies from Queen?s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.